公开(公告)号：JP2010075188A

公开(公告)日：2010-04-08

申请号：JP2009256176

申请日：2009-11-09

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： BILLING-MEDEL PATRICIA A ,  COHEN MAURICE ,  COLPITTS TRACEY L ,  FRIEDMAN PAULA N ,  GORDON JULIAN ,  GRANADOS EDWARD N ,  HODGES STEVEN C ,  KLASS MICHAEL R ,  KRATOCHVIL JON D ,  ROBERTS-RAPP LISA ,  RUSSELL JOHN C ,  STROUPE STEVEN D

IPC: C12N15/09 ,  G01N33/53 ,  A61K38/00 ,  A61K39/395 ,  A61P35/00 ,  C07K14/47 ,  C07K16/18 ,  C07K16/30 ,  C12M1/26 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/02 ,  C12Q1/68 ,  G01N33/574

CPC classification number: C07K16/3015 ,  A61K38/00 ,  C07K14/47 ,  C12Q1/6886 ,  C12Q2600/136

Abstract: PROBLEM TO BE SOLVED: To provide a method useful for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining predisposition to diseases or conditions of the breast such as breast cancer. SOLUTION: A set of contiguous or partially overlapping RNA sequences, and polypeptides encoded thereby, designated as BS106 and transcribed from breast tissue is provided. The sequences are useful for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases or conditions of the breast such as the breast cancer. Furthermore, there is provided an antibody which specifically binds to BS106-encoded polypeptide or protein, and an agonist or inhibitor which prevents action of the tissue-specific BS106 polypeptide, which molecules are useful for the therapeutic treatment of breast diseases, tumors or metastases. COPYRIGHT: (C)2010,JPO&INPIT

Abstract translation: 要解决的问题：提供一种用于检测，诊断，分期，监测，预后，预防或治疗或确定乳腺疾病或病症倾向的方法，如乳腺癌。 提供了一组连续或部分重叠的RNA序列及其编码的多肽，称为BS106并从乳腺组织转录。 该序列可用于检测，诊断，分期，监测，预后，预防或治疗或确定个体对乳腺疾病或病症（例如乳腺癌）的倾向。 此外，提供了特异性结合BS106编码的多肽或蛋白质的抗体，以及防止组织特异性BS106多肽的作用的激动剂或抑制剂，该分子可用于治疗乳腺疾病，肿瘤或转移瘤。 版权所有（C）2010，JPO＆INPIT

公开(公告)号：WO0056352A3

公开(公告)日：2002-03-07

申请号：PCT/US0007945

申请日：2000-03-24

Applicant: ABBOTT LAB

Inventor： BILLING-MEDEL PATRICIA A ,  COHEN MAURICE ,  COLPITTS TRACEY L ,  GORDON JULIAN ,  GRANADOS EDWARD N ,  RUSSELL JOHN C ,  STROUPE STEPHEN D

IPC: G01N33/53 ,  A61K38/00 ,  C07K14/47 ,  C07K14/495 ,  C07K16/24 ,  C07K16/30 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12P21/02 ,  C12Q1/68 ,  G01N33/574 ,  A61K38/17 ,  C12N15/63 ,  G01N33/577

CPC classification number: G01N33/57434 ,  A61K38/00 ,  C07K14/4748 ,  C07K16/3069 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/136

Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as PCIGF and transcribed from prostate tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the prostate, such as prostate cancer. Also provided are antibodies which specifically bind to PCIGF-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PCIGF polypeptide, which molecules are useful for the therapeutic treatment of prostate diseases, tumors or metastases.

Abstract translation: 描述了一组连续和部分重叠的cDNA序列和由此编码的多肽，称为PCIGF并从前列腺组织转录。 这些序列可用于检测，诊断，分期，监测，预后，体内成像，预防或治疗或确定个体对前列腺疾病和病症如前列腺癌的倾向。 还提供了特异性结合PCIGF编码的多肽或蛋白质的抗体，以及预防组织特异性PCIGF多肽的作用的激动剂或抑制剂，该分子可用于治疗前列腺疾病，肿瘤或转移瘤。

公开(公告)号：WO0132916A3

公开(公告)日：2002-07-11

申请号：PCT/US0030280

申请日：2000-11-02

Applicant: ABBOTT LAB

Inventor： RUSSELL JOHN C ,  GRANADOS EDWARD N

IPC: G01N21/78 ,  C12Q1/26 ,  C12Q1/28 ,  C12Q1/32 ,  C12Q1/37 ,  C12Q1/44 ,  C12Q1/48 ,  C12Q1/527

CPC classification number: C12Q1/26 ,  C12Q1/28 ,  C12Q1/32 ,  C12Q1/44 ,  G01N2405/04

Abstract: The present invention relates to an improved enzymatic diagnostic assay to detect carcinoma by measuring various lysophospholipids, including lysophosphatidic acid (LPA), in a patient. In a preferred embodiment, this assay measures the human plasma level of LPA in an automated format with a minimal number of reagents and with reduced incubation periods. The present invention also comprises several additional technical improvements to the current LPA assays disclosed in the prior art.

Abstract translation: 本发明涉及通过测量患者中各种溶血磷脂（包括溶血磷脂酸（LPA））来检测癌症的改进的酶学诊断测定法。 在优选的实施方案中，该测定法以最小数量的试剂和减少的潜伏期以自动化形式测量LPA的人血浆水平。 本发明还包括对现有技术中公开的当前LPA测定法的若干附加技术改进。

公开(公告)号：WO9741256A3

公开(公告)日：1997-12-11

申请号：PCT/US9707014

申请日：1997-04-25

Applicant: ABBOTT LAB

Inventor： GRANADOS EDWARD N ,  BOUMA STANLEY R ,  CARRINO JOHN J ,  SOLOMON NATALIE A

IPC: C12N15/09 ,  C12Q1/68

CPC classification number: C12Q1/6825 ,  C12Q2563/173 ,  C12Q2537/143 ,  C12Q2521/301

Abstract: Provided herein are methods for detecting multiple target nucleic acid sequences in a test sample. Also provided is a hybridization platform useful for detecting multiple target sequences in a test sample. The hybridization platform comprises a solid support material having a defined pattern of capture probes immobilized thereon.

公开(公告)号：WO0165262A3

公开(公告)日：2002-04-11

申请号：PCT/US0106516

申请日：2001-02-28

Applicant: ABBOTT LAB

Inventor： BILLING-MEDEL PATRICIA A ,  COHEN MAURICE ,  COLPITTS TRACEY L ,  FRIEDMAN PAULA N ,  GORDON JULIAN ,  GRANADOS EDWARD N ,  HODGES STEVEN C ,  KLASS MICHAEL R ,  KRATOCHVIL JON D ,  ROBERTS-RAPP LISA ,  RUSSELL JOHN C ,  STROUPE STEVEN D

IPC: G01N33/53 ,  C07K14/47 ,  C07K16/18 ,  C07K19/00 ,  C12N5/10 ,  C12N15/09 ,  C12Q1/02 ,  G01N33/574 ,  C07K16/30

CPC classification number: G01N33/57415 ,  C07K14/4748

Abstract: Multimeric polypeptides antigens comprising polypeptides designated as BS106 and transcribed from breast tissue is described. These sequences are useful for the detecting, diagnosing, staging, monitoring prognosticating or determining the predisposition of an individual to diseases and conditions of the breast such as breast cancer. Also provided are antibodies which specifically bind to BS106-encoded polypeptide or protein.

Abstract translation: 描述了包含称为BS106并从乳腺组织转录的多肽的多聚体多肽抗原。 这些序列可用于检测，诊断，分期，监测预测或确定个体对乳腺疾病和状况（例如乳腺癌）的倾向。 还提供了特异性结合BS106编码的多肽或蛋白质的抗体。

公开(公告)号：WO9914357A9

公开(公告)日：1999-07-08

申请号：PCT/US9819496

申请日：1998-09-18

Applicant: ABBOTT LAB

Inventor： BILLING-MEDEL PATRICIA A ,  COHEN MAURICE ,  COLPITTS TRACEY L ,  FRIEDMAN PAULA N ,  GORDON JULIAN ,  GRANADOS EDWARD N ,  HODGES STEVEN C ,  KLASS MICHAEL R ,  KRATOCHVIL JON D ,  MERCHANT BARBARA T ,  ROBERTS-RAPP LISA ,  RUSSELL JOHN C ,  STROUPE STEPHEN D

IPC: A61K38/00 ,  C07K14/705 ,  C07K16/30 ,  C12Q1/68 ,  A61K38/17 ,  C07K14/47 ,  C07K16/18 ,  C12N5/10 ,  G01N33/574

CPC classification number: C07K16/3015 ,  A61K38/00 ,  A61K2039/51 ,  C07K14/705 ,  C07K16/3069 ,  C12Q1/6886 ,  C12Q2600/136

Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as PS214 and transcribed from prostate, breast, or ovary tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the prostate, breast, or ovary, such as prostate, breast, or ovarian cancer. Also provided are antibodies which specifically bind to PS214-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PS214 polypeptide, which molecules are useful for the therapeutic treatment of prostate, breast, or ovary diseases, tumors or metastases.

Abstract translation: 描述了一组连续和部分重叠的cDNA序列和由此编码的多肽，命名为PS214并从前列腺，乳腺或卵巢组织转录。 这些序列可用于检测，诊断，分期，监测，预后，体内成像，预防或治疗或确定个体对前列腺，乳腺或卵巢的疾病和状况的倾向，例如前列腺，乳腺， 或卵巢癌。 还提供了特异性结合PS214编码的多肽或蛋白质的抗体，以及预防组织特异性PS214多肽的作用的激动剂或抑制剂，该分子可用于前列腺，乳腺或卵巢疾病，肿瘤或转移的治疗性治疗 。

公开(公告)号：WO0129264A3

公开(公告)日：2001-11-29

申请号：PCT/US0028627

申请日：2000-10-16

Applicant: ABBOTT LAB

Inventor： GRANADOS EDWARD N ,  SCHEFFEL CHRISTI POWELL

IPC: G01N33/53 ,  C12N15/09 ,  C12Q1/68 ,  G01N33/566

CPC classification number: C12Q1/6886 ,  C12Q2600/16

Abstract: Nucleic acid sequences are provided that are useful as amplification primers and hybridization probes for detecting CK19 target sequence in a test sample. The primers and probes can be employed in amplification based methods for detecting the presence of CK19 sequences in a test sample. The amplification product can be detected with the assistance of microparticle capture techniques.

Abstract translation: 提供了可用作检测样品中CK19靶序列的扩增引物和杂交探针的核酸序列。 引物和探针可用于基于扩增的检测样品中CK19序列存在的方法。 可以借助微粒捕获技术检测扩增产物。

公开(公告)号：WO0041516A3

公开(公告)日：2000-11-02

申请号：PCT/US0001309

申请日：2000-01-19

Applicant: ABBOTT LAB

Inventor： BILLING-MEDEL PATRICIA A ,  COHEN MAURICE ,  COLPITTS TRACEY L ,  FRIEDMAN PAULA N ,  GORDON JULIAN ,  GRANADOS EDWARD N ,  HODGES STEVEN C ,  KLASS MICHAEL R ,  KRATOCHVIL JON D ,  ROBERTS-RAPP LISA ,  RUSSELL JOHN C ,  SCHEFFEL CHRISTI P ,  STROUPE STEPHEN D

IPC: G01N33/53 ,  A61K31/711 ,  A61K39/395 ,  A61K45/00 ,  A61K48/00 ,  A61P35/00 ,  C07K14/47 ,  C07K16/18 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12P21/02 ,  C12P21/08 ,  C12Q1/68 ,  G01N33/574 ,  G01N33/58 ,  G01N37/00

CPC classification number: C07K14/47

Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as BU101 and transcribed from breast tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the breast, such as breast cancer. Also provided are antibodies which specifically bind to BU101-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific BU101 polypeptide, which molecules are useful for the therapeutic treatment of breast diseases, tumors or metastases.

Abstract translation: 描述了一组连续和部分重叠的cDNA序列和由此编码的多肽，命名为BU101并从乳腺组织转录。 这些序列可用于检测，诊断，分期，监测，预后，体内成像，预防或治疗或确定个体对乳腺疾病和病症如乳腺癌的倾向。 还提供了特异性结合BU101编码的多肽或蛋白质的抗体，以及预防组织特异性BU101多肽的作用的激动剂或抑制剂，该分子可用于治疗乳腺疾病，肿瘤或转移瘤。

公开(公告)号：WO9931274A2

公开(公告)日：1999-06-24

申请号：PCT/US9826441

申请日：1998-12-11

Applicant: ABBOTT LAB

Inventor： BILLING-MEDEL PATRICIA A ,  COHEN MAURICE ,  COLPITTS TRACEY L ,  FRIEDMAN PAULA N ,  GORDON JULIAN ,  GRANADOS EDWARD N ,  HODGES STEVEN C ,  KLASS MICHAEL R ,  KRATOCHVIL JON D ,  ROBERTS-RAPP LISA ,  RUSSELL JOHN C ,  STROUPE STEPHEN D

IPC: C07K14/47 ,  C07K16/18 ,  C12Q1/68 ,  C12N5/10 ,  G01N33/574

CPC classification number: C07K16/18 ,  C07K14/47

Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as PA153 and transcribed from pancreatic tissue, are described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the pancreas, such as pancreatic cancer. Also provided are antibodies which specifically bind to PA153-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PA153 polypeptide, which molecules are useful for the therapeutic treatment of pancreatic diseases, tumors or metastases.

Abstract translation: 描述了一组连续和部分重叠的cDNA序列和由其编码的多肽，命名为PA153并从胰腺组织转录。 这些序列可用于检测，诊断，分期，监测，预测，体内成像，预防或治疗或确定个体对胰腺疾病和病症（例如胰腺癌）的倾向性。 还提供了特异性结合PA153编码的多肽或蛋白质的抗体，以及阻止组织特异性PA153多肽作用的激动剂或抑制剂，所述分子可用于治疗性治疗胰腺疾病，肿瘤或转移瘤。

公开(公告)号：WO9914357A3

公开(公告)日：1999-05-27

申请号：PCT/US9819496

申请日：1998-09-18

Applicant: ABBOTT LAB

Inventor： BILLING-MEDEL PATRICIA A ,  COHEN MAURICE ,  COLPITTS TRACEY L ,  FRIEDMAN PAULA N ,  GORDON JULIAN ,  GRANADOS EDWARD N ,  HODGES STEVEN C ,  KLASS MICHAEL R ,  KRATOCHVIL JON D ,  MERCHANT BARBARA T ,  ROBERTS-RAPP LISA ,  RUSSELL JOHN C ,  STROUPE STEPHEN D

IPC: A61K38/00 ,  C07K14/705 ,  C07K16/30 ,  C12Q1/68 ,  A61K38/17 ,  C07K14/47 ,  C07K16/18 ,  C12N5/10 ,  G01N33/574

CPC classification number: C07K16/3015 ,  A61K38/00 ,  A61K2039/51 ,  C07K14/705 ,  C07K16/3069 ,  C12Q1/6886 ,  C12Q2600/136

Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as PS214 and transcribed from prostate, breast, or ovary tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the prostate, breast, or ovary, such as prostate, breast, or ovarian cancer. Also provided are antibodies which specifically bind to PS214-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PS214 polypeptide, which molecules are useful for the therapeutic treatment of prostate, breast, or ovary diseases, tumors or metastases.

Abstract translation: 描述了一组连续和部分重叠的cDNA序列和由其编码的多肽，命名为PS214并从前列腺癌，乳腺癌或卵巢组织转录。 这些序列可用于检测，诊断，分期，监测，预后，体内成像，预防或治疗或确定个体对前列腺癌，乳腺癌或卵巢疾病和病症的倾向，如前列腺癌，乳腺癌， 或卵巢癌。 还提供了特异性结合PS214编码的多肽或蛋白质的抗体，以及阻止组织特异性PS214多肽作用的激动剂或抑制剂，所述分子可用于治疗性治疗前列腺癌，乳腺癌或卵巢疾病，肿瘤或转移瘤 。